Professor Sir Nicholas J White
Podcast interview
Improving the treatment of infectious diseases
With nearly 50 years in malaria research and more recent focus on COVID-19, research at MORU led to more effective treatments. In COVID-19, trials debunked drugs like ivermectin or favipiravir, but validated remdesivir, molnupiravir and protease inhibitors. As malaria faces drug resistance, triple therapies offer hope. MORU research aims for tangible health impacts, with an approach applicable to other infectious diseases.
Research groups
Colleges
Nicholas White
FRS
Professor of Tropical Medicine
- Professor at Mahidol University in Thailand
Professor White’s diverse interests include the epidemiology, pathophysiology and management of uncomplicated and severe malaria, meliodosis, enteric fever, tetanus, dengue haemorrhagic fever, Japanese encephalitis and tuberculosis. His particular interests at present include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations. and the biology of relapse in vivax malaria.
Vivax malaria
Recent publications
-
Characterising viral clearance kinetics in acute influenza
Wongnak P. et al, (2025)
-
Submicroscopic malaria in pregnancy and associated adverse pregnancy events: A case-cohort study of 4,352 women on the Thailand–Myanmar border
Gilder ME. et al, (2025), PLOS Medicine, 22, e1004529 - e1004529
-
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers.
Watson JA. et al, (2025), Antimicrob Agents Chemother
-
Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine
Tarning J. et al, (2025), Clinical Pharmacology & Therapeutics
-
A comparison of national seasonal influenza treatment guidelines across the Asia Pacific region.
Beer E. et al, (2025), PLOS global public health, 5